MAIA Biotechnology, Inc.
MAIA•NYSEAMERICAN•Healthcare•Biotechnology

About MAIA Biotechnology

MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois.

Company Information

SectorHealthcare
IndustryBiotechnology
CEOVlad Vitoc
Founded2018
IPO DateJuly 28, 2022
Employees13
CountryUnited States
Fiscal YearJanuary - December

Stock Details

ExchangeNYSEAMERICAN (NYSEAMERICAN)
CurrencyUSD - USD
TypeStock
SubtypeCommon Stock

Contact Information

Websitemaiabiotech.com
Phone312 416 8592
Address
444 West Lake Street, Suite 1700 Chicago, Illinois 60606 United States

Corporate Identifiers

CIK0001878313
CUSIP552641102
ISINUS5526411021
SIC2834

Leadership Team & Key Executives

Dr. Vlad Vitoc M.B.A., M.D.
Co-Founder, President, Chief Executive Officer and Chairman of the Board of Directors
Jeffrey C. Himmelreich
Head of Finance and Principal Financial and Accounting Officer
Dr. Sergei M. Gryaznov Ph.D.
Chief Scientific Officer
Linda Moreira
Company Secretary